WO2010142784A2 - Utilisation d'un gel plaquettaire (prp) pour une reconstruction du volume mammaire - Google Patents

Utilisation d'un gel plaquettaire (prp) pour une reconstruction du volume mammaire Download PDF

Info

Publication number
WO2010142784A2
WO2010142784A2 PCT/EP2010/058226 EP2010058226W WO2010142784A2 WO 2010142784 A2 WO2010142784 A2 WO 2010142784A2 EP 2010058226 W EP2010058226 W EP 2010058226W WO 2010142784 A2 WO2010142784 A2 WO 2010142784A2
Authority
WO
WIPO (PCT)
Prior art keywords
platelet
biological implant
gel
platelet gel
breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/058226
Other languages
English (en)
Other versions
WO2010142784A3 (fr
Inventor
Juan Francisco JULIÁN IBÁÑEZ
Jorge NAVINÉS LÓPEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat Autonoma de Barcelona UAB
Banc de Sang i Teixits
Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Original Assignee
Universitat Autonoma de Barcelona UAB
Banc de Sang i Teixits
Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat Autonoma de Barcelona UAB, Banc de Sang i Teixits, Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP filed Critical Universitat Autonoma de Barcelona UAB
Priority to US13/377,293 priority Critical patent/US9199007B2/en
Priority to EP10722715.9A priority patent/EP2470229B1/fr
Priority to ES10722715.9T priority patent/ES2648090T3/es
Publication of WO2010142784A2 publication Critical patent/WO2010142784A2/fr
Publication of WO2010142784A3 publication Critical patent/WO2010142784A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Definitions

  • the present invention relates to the field of reconstruction and augmentation of soft tissue, particularly breast tissue.
  • the main types of artificial implants consist of a silicone capsule filled with silicone gel or saline solution.
  • Combined implants have also been disclosed in the literature, such as that disclosed in EP-A-797460, which uses matrices seeded with cells, preferably muscle cells.
  • abdominal adipose skin and tissue and part of the straight abdominal muscles are normally used.
  • latissimus dorsi musculocutaneous flap tissue has also been used.
  • Platelets play a basic role in the wound repair process, regardless of their aetiology. When a wound occurs, the platelets become activated and release diverse growth factors, such as PDGF (platelet-derived growth factor) , EFT (epidermal growth factor) and TGF (transforming growth factor) , which converts fibrinogen into fibrin, forming a cross-linking that finally gives rise to a clot.
  • PDGF platelet-derived growth factor
  • EFT epidermatitis factor
  • TGF transforming growth factor
  • a clotting cascade activator such as an excess of calcium ions (calcium chloride) , thrombin, batroxobin, etc.
  • platelet gel is widely used in dental and oral and maxillofacial surgery, where it is used basically for bone implantation and regeneration. It is also applied to chronic wounds, ulcers and soft tissues
  • a layer is generally spread over the wound bed to aid healing. Its use in facial plastic surgery and breast augmentation and reduction operations as a sealant and haemostatic agent has been disclosed, where it reduced the need for drainage and compressive bandaging as well as the incidence of complications (Acta Dermatoven APA Vol. 16, 207, No. 4).
  • the autologous platelet gel can be moulded into a geometric, rectangular, conical or roller shape to temporarily fill, by way of a plug, cavities due to dental extraction or bone cavities.
  • a temporary filling it does indicate that, for example, another bioadhesive sealant formed by clotting of fibrinogen with thrombin is reabsorbed in just ten days.
  • the gel is prepared from just 6 cm 3 of PRP.
  • the problem to be solved by the present invention is the provision of a drug or biological implant to be implanted in a soft tissue, preferably a breast, for reconstruction or augmentation of the volume of said tissue, that will overcome the drawbacks of the state of the art .
  • the solution is based on the fact that the present inventors unexpectedly found that the use of conveniently moulded platelet gel allows the re-establishment of soft tissue volume over time (see example 3) .
  • the inventors verified this upon introduction into a cavity produced by tumorectomy in a breast, obtaining good results even using large volumes, for example 250 cm 3 , so that it can be used by way of a biological implant such as a breast implant.
  • the present inventors have achieved the volumetric substitution of removed tissue using the platelet gel, favoring internal scarring and improving the aesthetical result without increasing surgical morbidity, as well as augmenting breast volume.
  • a first aspect of the invention relates to the use of a platelet gel for preparing a drug or a biological implant to be implanted in a soft tissue for reconstruction, augmentation or correction of abnormalities in the size and shape of said soft tissue, characterized in that said drug or biological implant comprises a platelet gel.
  • this first aspect of the invention can be worded as platelet gel for use as a biological implant to be implanted in a soft tissue for reconstruction, augmentation or correction of abnormalities in the size and shape of said soft tissue.
  • the second aspect of the invention relates to a biological implant for soft tissue comprising a platelet gel .
  • a third aspect of the invention relates to a kit for preparing a biological implant according to the present invention, comprising at least one mould in the shape of a round concave receptacle with a volume comprised between 75 and 700 cm 3 , at least one syringe, - one clotting activator, and optionally, one drug.
  • a fourth aspect of the invention relates to a process for preparing the biological implant, in accordance with the present invention, comprising the following steps:
  • platelet gel in accordance with the invention, is particularly advantageous in tumorectomy and mastectomy operations: - It allows remodeling the breast during the same surgical operation as the mastectomy and/or subcutaneous mastectomy, avoiding other oncoplastic techniques which require a subsequent or more complex surgical operation and the potential complications thereof; - It minimizes the anti-aesthetic retractions susceptible from more complex surgical operations;
  • the gel can be prepared in situ allows to have greater flexibility for preparing any desired volume, based on the tumour volume calculated after extraction, advantageously for tumorectomies, as opposed to artificial silicone implants of a determined size .
  • It allows the application of a preserving surgical treatment (tumorectomy) to larger size tumours that were previously only candidates for mastectomy due to being disproportionate to the size of the breast;
  • Platelet gel is obtained from platelet-rich plasma (PRP) whereto a clotting process-activating substance (for example, calcium chloride) is added.
  • PRP platelet-rich plasma
  • a clotting process-activating substance for example, calcium chloride
  • PRP as used herein, is understood to be a concentration of platelets greater than the concentration in peripheral blood suspended in a plasma solution. PRP typically has a minimum platelet count of 7.5 x 10 5 - I x 10 6 per ⁇ L .
  • Bio implant as used herein, is understood to be a product of substantially biological origin for the replacement or augmentation of a missing or imperfect part of the body.
  • the platelet dosage required for preparing the platelet gel can be obtained by means of plateletpheresis .
  • Plateletpheresis comprises extraction and separation of blood into its different components by centrifugation at different speeds for the purpose of obtaining platelet- rich plasma (PRP) .
  • PRP platelet- rich plasma
  • PRP can be obtained from the same patient whom the gel (autologous platelet gel) will be implanted or from a healthy allogeneic donor.
  • the platelets are obtained from a healthy allogeneic donor, optionally related to the patient.
  • Plateletpheresis can be carried out, for example, using the Haemonetics TM MCS+ cell separator or Medtronic Inc.'s MagellanTM Autologous Platelet Separation System.
  • an anticoagulant is added preferably based on citric acid, such as ACD-A (citric acid, sodium citrate and dextrose) .
  • PRP is required to have a minimum platelet count of 7.5 x 10 5 - I x 10 6 per ⁇ L .
  • the PRP is obtained from an allogeneic donor it is preferably treated by irradiation to deactivate any existing viral material or residual leukocyte. This treatment can be carried out during any stage of the gel preparation process.
  • the PRP is activated by adding a clotting activator, which is understood to be a substance capable of restoring anti-clotting activity, such as calcium chloride or other calcium salt which acts in a similar way, such as calcium gluconate or calcium carbonate.
  • calcium chloride is added as a 105 by weight aqueous solution.
  • clotting activators can also be used, including thrombin or batroxobin, by heating the mixture at 37 0 C.
  • the platelet gel can also be obtained by means of the processes disclosed in literature, such as those disclosed in EP-B-1239895, which use batroxobin instead of thrombin .
  • the PRP volume to be used is determined based on the final volume to be augmented or restored. Preferably, a correction factor comprised between 1.6 and 2.2 is applied.
  • the mixture is allowed to clot in a sterilised mould having adequate dimensions.
  • the mould can be made, for example, of ceramic, plastic, silicone glass or stainless steel. Preferably, it is allowed to clot in a sterile porcelain or stainless steel receptacle. More preferably, a porcelain mould is used.
  • the shape of the mould in general is such that the resulting gel adopts the desired shape of the implant.
  • the mould is preferably formed in the shape of a round concave receptacle with a volume comprised between 75 and 700 cm3.
  • the mould has a substantially semispherical shape.
  • the shape of the mould is such that the resulting gel takes the form of a breast implant with different volumes.
  • the platelet gel for implantation in accordance with the invention, has a volume comprised between 25 and 600 cm3. Formation of the gel is fast, generally being formed in less than fifteen minutes.
  • the platelet gel can optionally be used to release drugs such as antibiotics, anti-bacterials, analgesics, anti-inflammatories, anti-cancer compounds and tumoricidal 5 or tumor static compounds. These compounds can be added to the PRP before adding the calcium salt.
  • the PRP is added to an antibiotic, such as Cloxacillin.
  • the antibiotic is selected from the group formed by betalactamic antibiotics.
  • antibiotic is added, it is preferably added at a concentration ten times greater than that of the plasma.
  • the platelet-rich plasma (PRP) obtained is mixed with an adequate amount of a 10% by weight calcium chloride solution and is heated at
  • PDGF platelet-derived growth factor
  • EGF epidermal growth factor
  • TGF transforming growth factor
  • the platelet gel preparation process in accordance with the fourth aspect of the invention, also comprises the following subsequent steps: - Cooling the gelled mixture, preferably at room
  • the platelet gel is used to prepare a drug or biological implant to be implanted in a soft tissue for reconstruction, augmentation or correction of 5 abnormalities in the size and shape of said soft tissue, characterized in that said drug or biological implant comprises a platelet gel.
  • Said drug or biological implant can be constituted by, for example, more than 50% by weight of the platelet gel, or more than 70% or more than
  • said drug or biological implant essentially consists of a platelet gel. More preferably, said drug or biological implant consists of a platelet gel .
  • 15 invention can be surgically implanted following the processes known in the state of the art; for example, those used for silicone gel implants, particularly in the case of a breast biological implant, it may be implanted at subglandular or subpectoral level.
  • the platelet gel is used just after its clotting, in order to take maximum advantage of the benefits of releasing the growth factors that accompany the clotting process.
  • 25 drug is implanted, in accordance with the invention, is preferably selected from the group consisting of breast, gluteal, abdominal and facial tissue. More preferably, it is selected from breast, gluteal and abdominal tissue. Even more preferably, it is implanted in a breast.
  • the platelet gel is used for the reconstruction of a breast subjected to tumorectomy.
  • the PRP volume to be used to prepare the platelet gel can be calculated based on the tumour volume, which can be measured or calculated by means of the liquid
  • a variable correction factor (between 1.6 and 2.2) is preferably applied in order to determine the volume of platelet gel to be implanted.
  • the volumetric control can be obtained by comparing the pre- and post-operative breast volumes by means of volumetric measurement using Nuclear Magnetic Resonance .
  • the platelet gel is prepared from PRP obtained from a healthy allogeneic donor.
  • the biological implant for soft tissue in accordance with the second aspect of the invention, comprises a platelet gel.
  • Said biological implant can be constituted by, for example, more than 50% by weight of the platelet gel, or more than 70% or more than 90%.
  • said biological implant essentially consists of a platelet gel. More preferably, said biological implant consists of a platelet gel.
  • the biological implant according to the invention has a volume comprised between 25 and 600 cm 3 .
  • the implant in accordance with the invention, can be a breast, gluteal, abdominal or facial implant, preferably a breast, gluteal or abdominal implant. More preferably, said biological implant is a breast implant.
  • Kit for preparing the biological implant also provides a kit for facilitating the preparation of the biological implant, in accordance with the present invention, comprising: a mould in the shape of a round concave receptacle with a volume comprised between 75 and 700 cm 3 , - at least one syringe one clotting activator, and optionally, a drug.
  • said kit also comprises a bag containing platelet-rich plasma.
  • the clotting activation agent used in said kit is an aqueous solution of 10% calcium chloride.
  • said kit contains at least one pre-filled syringe containing said calcium chloride solution.
  • Example 1 Production of platelet-rich plasma (PRP) The PRP was obtained from healthy allogeneic patients following a plateletpheresis process.
  • ACD-A was used as anti-coagulant.
  • the PRP obtained had a minimum platelet count of
  • Plateletpheresis was carried out the day before the surgical operation.
  • the volume of PRP to be used to form the platelet gel was calculated based on the volume of the tumour of each patient by means of the volume displaced by the tumorectomy piece immersed in saline solution in a test tube. A correction factor of approximately 1.6 was then applied.
  • the mixture was heated at 37 0 C in bain-marie in a sterile ceramic receptacle until it gelled.
  • the clotting process took approximately between 4 and 10 minutes.
  • the process was accelerated by adding human thrombin.
  • Example 3 Breast reconstruction using platelet gel A sample was taken from 19 patients, four forming the control group and 15 the cases under study.
  • the patients were women with unilateral breast neoplasia who were candidates for preserving treatment.
  • the patients of the control group were subjected to tumorectomy in a breast without any kind of volumetric reconstruction.
  • Example 4 Comparative analysis of patients subjected to a breast neoplasia operation with and without volume reconstruction using platelet gel
  • Table 1 shows the tumorectomy volumes and the platelet gel volume added for breast reconstruction, and reflects the results of the post-operative volumetric appearance in relation to the pre-operative volumetric appearance at different times.
  • the criterion used to evaluate the results was a subjective criterion based on two observers. Therefore, it was defined as:
  • Table 2 shows the tumorectomy volumes of patients subjected to a breast neoplasia operation without volume reconstruction using platelet gel as well as the results of the post-operative appearance in relation to pre ⁇ operative appearance at different times.
  • the data shown in Table 1 reveal that the post- operative volumetric appearance in relation to the pre ⁇ operative appearance in patients subjected to a breast neoplasia operation with volume reconstruction using platelet gel remained satisfactory in most of the patients throughout the observed time periods.
  • the data shown in Table 2 reveal that, in the case of patients not subjected to volume reconstruction using platelet gel, even though in some cases the appearance of the breast was apparently satisfactory immediately after the operation, one month after the operation the appearance of the breast was no longer satisfactory in most of them.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)

Abstract

La présente invention concerne l'application d'un gel plaquettaire pour augmenter ou restaurer le volume d'un tissu mou, particulièrement le tissu mammaire, des implants biologiques comprenant ledit gel, un kit de préparation desdits implants et un procédé de préparation desdits implants.
PCT/EP2010/058226 2009-06-11 2010-06-11 Utilisation d'un gel plaquettaire (prp) pour une reconstruction du volume mammaire Ceased WO2010142784A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/377,293 US9199007B2 (en) 2009-06-11 2010-06-11 Use of gelled PRP (platelet gel) for volumetric breast reconstruction
EP10722715.9A EP2470229B1 (fr) 2009-06-11 2010-06-11 Utilisation d'un gel plaquettaire (prp) pour une reconstruction du volume mammaire
ES10722715.9T ES2648090T3 (es) 2009-06-11 2010-06-11 Uso de PRP gelificado (gel de plaquetas) para la reconstrucción volumétrica de la mama

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200901433 2009-06-11
ES200901433 2009-06-11

Publications (2)

Publication Number Publication Date
WO2010142784A2 true WO2010142784A2 (fr) 2010-12-16
WO2010142784A3 WO2010142784A3 (fr) 2011-04-07

Family

ID=42711687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/058226 Ceased WO2010142784A2 (fr) 2009-06-11 2010-06-11 Utilisation d'un gel plaquettaire (prp) pour une reconstruction du volume mammaire

Country Status (4)

Country Link
US (1) US9199007B2 (fr)
EP (1) EP2470229B1 (fr)
ES (1) ES2648090T3 (fr)
WO (1) WO2010142784A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015015037A1 (fr) * 2013-08-01 2015-02-05 Biotechnology Institute, I Mas D, S.L. Formulation d'une composition sanguine riche en plaquettes et/ou facteurs de croissance, avec des protéines gélifiées, et procédé de préparation correspondant
US20200254138A1 (en) * 2019-02-11 2020-08-13 Biotechnology Institute, I Mas D, S.L. Tissular formulation or adhesive obtained from a blood composition containing platelets, and method for the preparation of said formulation
US10772992B2 (en) 2016-02-17 2020-09-15 The Governing Council Of The University Of Toronto Soft tissue filler
US20250381222A1 (en) * 2024-02-07 2025-12-18 Stephen Lawrence SCHLESINGER Use of platelet-based products for treatment of capsular contracture proximate breast implant

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472283B2 (en) * 2022-10-04 2025-11-18 Johanna Andrea Pulgar Method of performing a buttocks and hip augmentation using plasma gel

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5752974A (en) * 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
ITAL990010U1 (it) 1999-12-14 2001-06-14 Maria Cristina Sacchi Nuova metodica di laboratorio per preparare gel e membrane piastriniche ottenute dal concentrato piastrinico.
US6942880B1 (en) 2001-04-09 2005-09-13 Medtronic, Inc. Autologous platelet gel having beneficial geometric shapes and methods of making the same
WO2003017913A1 (fr) * 2001-08-27 2003-03-06 The Cleveland Clinic Foundation Compositions, methodes et appareil destines a des interventions chirurgicales
ITRM20040638A1 (it) * 2004-12-24 2005-03-24 Advance Holdings Ltd Gel piastrinico semisintetico e metodo per la sua preparazione.
US20070014784A1 (en) 2005-06-23 2007-01-18 Medtronic Vascular, Inc. Methods and Systems for Treating Injured Cardiac Tissue

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACTA DERMATOVEN APA, vol. 16, no. 4, pages 207
CLEVELAND CLINIC JOURNAL OF DRUG, vol. 75, no. 1, 2008, pages S17 - S23
PLASTIC AND RECONSTRUCTIVE SURGERY, vol. 119, no. 4, 2007, pages 1159 - 1166

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015015037A1 (fr) * 2013-08-01 2015-02-05 Biotechnology Institute, I Mas D, S.L. Formulation d'une composition sanguine riche en plaquettes et/ou facteurs de croissance, avec des protéines gélifiées, et procédé de préparation correspondant
JP2016528225A (ja) * 2013-08-01 2016-09-15 バイオテクノロジー インスティチュート、アイ エムエーエス ディー、 エス．エル． 血小板及び／又は成長因子が強化され、ゲル化タンパク質を含有する血液組成物の製剤、並びにその製造方法
US9861684B2 (en) 2013-08-01 2018-01-09 Biotechnology Institute, I Mas D, S.L. Formulation of a blood composition that is rich in platelet and/or growth factors and contains gelled proteins, and a method for its preparation
RU2697249C2 (ru) * 2013-08-01 2019-08-13 Байотекнолоджи Инститьют, И Мас Д, С.Л. Состав на основе композиции крови, которая является обогащенной тромбоцитами и/или факторами роста и содержит гелеобразные белки, и способ ее получения
US10772992B2 (en) 2016-02-17 2020-09-15 The Governing Council Of The University Of Toronto Soft tissue filler
US20200254138A1 (en) * 2019-02-11 2020-08-13 Biotechnology Institute, I Mas D, S.L. Tissular formulation or adhesive obtained from a blood composition containing platelets, and method for the preparation of said formulation
JP2022520776A (ja) * 2019-02-11 2022-04-01 バイオテクノロジー インスティチュート、アイ エムエーエス ディー、 エス．エル． 血小板を含有する血液組成物から得られる組織製剤又は接着剤、及びそのような製剤を調製する方法
JP7291972B2 (ja) 2019-02-11 2023-06-16 バイオテクノロジー インスティチュート、アイ エムエーエス ディー、 エス．エル． 血小板を含有する血液組成物から得られる組織製剤又は接着剤、及びそのような製剤を調製する方法
US11744917B2 (en) * 2019-02-11 2023-09-05 Biotechnology Institute, I Mas D, S.L. Tissular formulation or adhesive obtained from a blood composition containing platelets, and method for the preparation of said formulation
US20250381222A1 (en) * 2024-02-07 2025-12-18 Stephen Lawrence SCHLESINGER Use of platelet-based products for treatment of capsular contracture proximate breast implant
US12521417B2 (en) * 2024-02-07 2026-01-13 L & O Medical, LLC Use of platelet-based products for treatment of capsular contracture proximate breast implant

Also Published As

Publication number Publication date
EP2470229A2 (fr) 2012-07-04
WO2010142784A3 (fr) 2011-04-07
US20120087989A1 (en) 2012-04-12
ES2648090T3 (es) 2017-12-28
EP2470229B1 (fr) 2017-08-23
US9199007B2 (en) 2015-12-01

Similar Documents

Publication Publication Date Title
US11992580B2 (en) Method of soft tissue augmentation
Argenta et al. Vacuum-assisted closure: a new method for wound control and treatment: clinical experience
KR102136314B1 (ko) 상처 치유 조성물의 제조를 위한 방법, 튜브 및 장치
RU2660561C2 (ru) Использование стволовых клеток, полученных из жировой ткани и выращенных ex-vivo, для косметического липофилинга молочной железы или липофилинга и/или омоложения лица
US9199007B2 (en) Use of gelled PRP (platelet gel) for volumetric breast reconstruction
RU106528U1 (ru) Клеточный имплантат для восстановления дефектов кожного покрова
CN105056285A (zh) 一种可粘合组织裂隙的生长因子复合敷料及其制备方法
Fulton Breast contouring with" gelled" autologous fat: A 10-year update
CN101279104A (zh) 一种含有生长因子的胶原蛋白海绵的制备方法
BR112020015616B1 (pt) Composição de biotinta para folha de regeneração de derme, método para fabricar folha de regeneração de derme customizada usando a mesma e folha de regeneração de derme customizada fabricada usando o método de fabricação
Peters et al. Calcification of breast implant capsules: incidence, diagnosis, and contributing factors
JP2006528672A5 (fr)
Elyounsi et al. Determination of the adequate vascular perfusion time of cross-leg free latissimus dorsi myocutaneous flaps in reconstruction of complex lower extremity defects
RU2802144C1 (ru) Способ препекторальной реконструкции молочных желез после кожесохраняющей мастэктомии
RU2809428C1 (ru) Применение аллоимплантата на основе широкой фасции бедра человека при одномоментных реконструкциях с использованием силиконового эндопротеза у больных раком молочной железы
RU2831000C1 (ru) Способ отсроченной препекторальной реконструкции после мастэктомии при раке молочной железы с помощью перманентного имплантата
RU2743199C2 (ru) Способ реконструктивно-пластической хирургии у больных раком молочной железы с использованием ксеноперикарда БиоЛАБ-ПП/ПА и силиконового эндопротеза
US20250195714A1 (en) Devices and methods of treating wounds
Jegorov et al. Wichterle hydron for breast augmentation–case reports and brief review
RU34865U1 (ru) Структура материала для имплантации на гортани
Al-Karmouty et al. Dermal sling used in the management of breast cancer in Egyptian women with large breasts
Martino et al. Synthetic Meshes in Breast
Stefano Synthetic mesh in the complications of breast cosmetics surgery
Kaufman Reawakening the most hard-to-heal chronic wounds: long-term outcomes of a randomised, controlled trial with active negatively charged microsphere (NCAA) technology.
Signorini et al. Bio-Alcamid®

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10722715

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13377293

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010722715

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010722715

Country of ref document: EP